Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Recruiting now · Phase 2/Phase 3

Conditions studied: Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia

In brief

This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia

Key facts

Study ID

NCT03937544

Run by

National University of Malaysia

People needed

10

Starts

2019-03-19

Expected to finish

2027-03-18

Last updated by the study team

2025-05-29

Who can join

Age: 13 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with relapsed/refractory B-ALL in accordance with World Health Organization (WHO) classification by virtue of BM morphology, flow cytometry, cytogenetics and molecular genetics
• Age between ≥13 to ≤ 65 years
• No detectable leukaemia in the CSF (CNS-1)
• CNS leukaemia without clinically evident neurological symptoms (CNS-2; with <5 WBC per μL and cytology positive for blasts)
• Adequate organ function as defined by a creatinine clearance > 50 ml/min, serum total bilirubin < 5 times the normal value, left ventricular ejection fraction > 40%
• ECOG performance status ≤ 2
• Life expectancy > 3 months
• Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not receiving immunosuppression
• Female patients of child bearing age must have negative pregnancy test and is on highly effective contraception methods
• Male patients must use highly effective contraception methods

You may not qualify if…

• Patients with CNS-3 leukaemia.
• Active cancer (other than B-ALL).
• Evidence of severe lung, heart (NYHA class III/IV, arrhythmia, AV block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder.
• Presence of active autoimmune disease or atopic allergy.
• HIV serology positivity.
• Active Hepatitis B or C infection as evidenced by quantitative viral PCR assay.
• Uncontrolled sepsis
• Pregnant / nursing female.
• Ongoing prednisolone > 1mg/kg daily or equivalent.
• Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.

Where it is running

• UKM Medical Centre — Bandar Tun Razak, Kuala Lumpur, Malaysia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.